Pharma and biotech giant Roche’s Claudine Nick outlined the internal and external complexities of localizing for this highly regulated industry and highlighted the value-add of having an internal language services team. Continue reading
life sciences
Language service provider RWS tells investors at capital markets event about how it is integrating Moravia and informs about the results of a pilot project to deploy MT post-editing in production in its patent translation division. Continue reading
Partnership will streamline the international medical labeling publishing process Continue reading
Advertisement
As technology is boosting productivity and changing buyer expectations, dropping unit prices presents opportunities to vendors that bring the tech, specialization, and size to seize them but it is an existential threat to generalists lacking focus. Continue reading
Slator poll-takers say life sciences is the most high-growth vertical, share very positive outlook on neural MT, reveal word rate changes in 2017, and answer whether LSPs should build or buy their tech. Continue reading
AMPLEXOR’S Jason Arnsparger will present “Lost in Translation: The Case for Centralized Content Management” at the Pharma & Device Labeling Conference. Continue reading
Hydrocortisone or Dexamethasone? A Guangdong-based Chinese drug manufacturer gets a warning letter from the US Food and Drug Administration over a translation mistake in the label of an over-the-counter drug exported to the US. Continue reading
The acquisition of LUZ, Inc. and Corporate Translations, Inc. strengthens RWS’ market leadership and continued growth of life science language services. Continue reading
The combination of ICON’s and Mapi’s language services groups will create a potent rival to language service providers when competing for business with big pharma. Continue reading
With new regulations in China as well as global language issues, life sciences companies are facing new challenges in conducting clinical trials in Asia-Pacific. Continue reading
Rally Health Localization Manager on how localization is considered a revenue driver at the fast-growing healthcare startup, how costs are shifting from translation to review, and how OS-agnostic web and cloud-based translation management solutions will become industry standard. Continue reading
One of the most attractive pure-play, life sciences players changes hands as RWS bolsters position in fast-growing vertical. Price tag in line with 2015 acquisition of CTi. Continue reading
RWS recruits from within and appoints current CFO Richard Thompson to take reins from Reinhard Ottway, who will step down end of March 2017. RWS shares continue to climb, pushing market cap to within striking distance of USD 1bn mark. Continue reading
Generating a profit of nearly USD 40m on revenues of barely USD 150m, RWS needs its shares to climb just 20% to crack the billion-dollar mark. The compay has posted uninterrupted growth since 2003 and CEO says having in-house translators is part of the recipe for success. Continue reading
The EU is expected to enact a sweeping overhaul of its regulatory framework for medical devices in early 2017, which includes changes to requirements for multilingual documentation. Brexit also adds to uncertainty. Continue reading
This information will never be shared with third parties. No Spam.